Literature DB >> 15652417

CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-alpha.

Koichi Narikawa1, Kazuo Fujihara, Tatsuro Misu, Juan Feng, Juichi Fujimori, Ichiro Nakashima, Isabelle Miyazawa, Hiroshi Saito, Shigeru Sato, Yasuto Itoyama.   

Abstract

We measured four chemokines in the cerebrospinal fluid (CSF) in human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) with ELISA. CXCL10/IP-10, a T cell type 1 (Th1)-associated chemokine, was significantly elevated in HAM/TSP compared with controls, and the values were even significantly higher in HAM/TSP than in multiple sclerosis (MS) in which CXCL10/IP-10 up-regulation was previously reported. Among Th2-associated chemokines, CCL17/TARC and CCL11/Eotaxin in HAM/TSP were not different from those in controls. As shown in MS, CCL2/MCP-1 was significantly lower in HAM/TSP than in control. Following interferon (IFN)-alpha therapy in HAM/TSP, CCL2/MCP-1 became significantly higher than that before therapy, which may reflect a Th2 induction, while CXCL10/IP-10 remained elevated.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15652417     DOI： 10.1016/j.jneuroim.2004.10.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  11 in total

1.  Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state.

Authors:  J B Guerreiro; S B Santos; D J Morgan; A F Porto; A L Muniz; J L Ho; A L Teixeira; M M Teixeira; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection.

Authors:  Silvane Braga Santos; Paulo Oliveira; Tania Luna; Anselmo Souza; Márcia Nascimento; Isadora Siqueira; Davi Tanajura; André Luiz Muniz; Marshall J Glesby; Edgar M Carvalho
Journal:  J Med Virol       Date:  2012-11       Impact factor: 2.327

3.  Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection.

Authors:  Anselmo Souza; Natália Carvalho; Yuri Neves; Silvane Braga Santos; Maria de Lourdes Bastos; Sérgio Arruda; Eduardo Martins Netto; Marshall J Glesby; Edgar Carvalho
Journal:  AIDS Res Hum Retroviruses       Date:  2017-06-26       Impact factor: 2.205

4.  Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy.

Authors:  Sonja Tattermusch; Jason A Skinner; Damien Chaussabel; Jacques Banchereau; Matthew P Berry; Finlay W McNab; Anne O'Garra; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2012-01-26       Impact factor: 6.823

5.  CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Tomoo Sato; Ariella Coler-Reilly; Atae Utsunomiya; Natsumi Araya; Naoko Yagishita; Hitoshi Ando; Junji Yamauchi; Eisuke Inoue; Takahiko Ueno; Yasuhiro Hasegawa; Kusuki Nishioka; Toshihiro Nakajima; Steven Jacobson; Shuji Izumo; Yoshihisa Yamano
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10

6.  Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.

Authors:  Yukiko Terada; Koju Kamoi; Kyoko Ohno-Matsui; Kazunori Miyata; Chinami Yamano; Ariella Coler-Reilly; Yoshihisa Yamano
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

7.  Intrarater and interrater agreement and reliability of vestibular evoked myogenic potential triggered by galvanic vestibular stimulation (galvanic-VEMP) for HTLV-1 associated myelopathy testing.

Authors:  Júlia Fonseca de Morais Caporali; Ludimila Labanca; Kyonis Rodrigues Florentino; Bárbara Oliveira Souza; Denise Utsch Gonçalves
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

8.  Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP.

Authors:  Tadasuke Naito; Jun-Ichirou Yasunaga; Yuichi Mitobe; Kazumasa Shirai; Hiroe Sejima; Hiroshi Ushirogawa; Yuetsu Tanaka; Tatsufumi Nakamura; Kousuke Hanada; Masahiro Fujii; Masao Matsuoka; Mineki Saito
Journal:  Retrovirology       Date:  2018-11-06       Impact factor: 4.602

9.  Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Authors:  Keiko Tamaki; Tomoo Sato; Jun Tsugawa; Shinsuke Fujioka; Naoko Yagishita; Natsumi Araya; Junji Yamauchi; Ariella L G Coler-Reilly; Misako Nagasaka; Yasuhiro Hasegawa; Yoshihisa Yamano; Yoshio Tsuboi
Journal:  Front Microbiol       Date:  2019-09-11       Impact factor: 5.640

Review 10.  Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Yoshimi Enose-Akahata; Steven Jacobson
Journal:  Retrovirology       Date:  2019-11-29       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.